Evidence map›Paper›PMID 33988738›Full record

ArticleAnnals of hematology2021

Optimizing conditioning regimen with low-dose irradiation or busulfan enables the outcome of transplantation from a 6-7/8 HLA-matched donor comparable to that from an 8/8 HLA-matched unrelated donor in severe aplastic anemia patients under 40 years.

Xia Qin, Yi-Ping Zhu, Cheng-Juan Luo, Ming Zhou, Ke Huang, Chun Chen, Wei-Ping Zhang, Yuan Sun, Rong-Mu Luo, Xiang-Feng Tang and 7 more

Abstract readComparative StudyMulticenter Study
PubMed Publisher
In one paragraph

Article in Annals of hematology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 11 institutions in 1 country.

Xia QinDepartment of Hematology and Oncology, National Children's Medical Center, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, 1678 Dongfang Road, Shanghai, 200127, China.
Yi-Ping ZhuDepartment of Pediatric Hematology and Oncology, West China Second University Hospital/West China Women and Children's Hospital, Sichuan University, Chengdu, China.
Cheng-Juan LuoDepartment of Hematology and Oncology, National Children's Medical Center, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, 1678 Dongfang Road, Shanghai, 200127, China.
Ming ZhouDepartment of Hematology, Guangzhou First People's Hospital , School of Medicine, South China University of Technology, 1 Panfu Road, Guangzhou, 510180, Guangdong, China.
Ke HuangDepartment of Pediatric Hematology and Oncology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.
Chun ChenDepartment of Pediatric Hematology and Oncology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.
Wei-Ping ZhangDepartment of Hematology, Changhai Hospital, Navy Military Medical University, Shanghai, China.
Yuan SunDepartment of Hematology and Oncology, Beijing JingDu Children's Hospital, Beijing, China.
Rong-Mu LuoDepartment of Hematology and Oncology, BaYi Children's Hospital, The Seventh Medical Center of PLA General Hospital, Beijing, China.
Xiang-Feng TangDepartment of Pediatric Hematology and Oncology, The Sixth Medical Center of PLA General Hospital, Beijing, China.
Ting YangDepartment of Hematology, Fujian Medical University Union Hospital, Fuzhou, China.
Xian-Min SongDepartment of Hematology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Shao-Yan HuDepartment of Hematology and Oncology, Children's Hospital of Soochow University, Soochow, China.
Zi-Min SunDepartment of Hematology, Anhui Provincial Hospital, University of Science and Technology of China, Hefei, China.
Jiong HuDepartment of Hematology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Shun-Qing WangDepartment of Hematology, Guangzhou First People's Hospital , School of Medicine, South China University of Technology, 1 Panfu Road, Guangzhou, 510180, Guangdong, China. eywangshq@scut.edu.cn.
Jing ChenDepartment of Hematology and Oncology, National Children's Medical Center, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, 1678 Dongfang Road, Shanghai, 200127, China. chenjing@scmc.com.cn.ORCID http://orcid.org/0000-0003-2895-700X
Shanghai Jiao Tong University · CNGuangzhou First People's Hospital · CNSun Yat-sen University · CNBayi Children's Hospital · CNBeijing Children’s Hospital · CNChinese PLA General Hospital · CNFujian Medical University · CNSecond Military Medical University · CNSichuan University · CNSoochow University · CNUniversity of Science and Technology of China · CN

Funding

Major Research Plan 81970114Shanghai Jiao Tong University School of Medicine DLY201814Shanghai Municipal Administrator of Traditional Chinese Medicine ZY [2018- 2020]-FWTX-3002Shanghai Municipal Health Commission 20184Y0145
6 · The paper itself

Abstract

With the dramatic improvements in outcomes following alternative donor hematopoietic stem cell transplantation (HSCT), interest in the use of alternative donors in severe aplastic anemia (SAA) is increasing. We conducted a multicenter prospective study to explore the efficiency and safety of upfront HSCT from a 6-8/8 HLA-matched unrelated donor (MUD) or 6-7/8 HLA-matched related donor (MRD) in acquired SAA patients under 40 years. Between August 2014 and July 2017, 115 patients were enrolled, including 48 (41.7%) patients receiving grafts from an 8/8 MUD, 25 (21.7%) from a 6-7/8 MRD, and 42 (36.5%) from a 6-7/8 MUD. The incidence of grade II-IV acute graft-versus-host disease (GVHD) was higher in the 6-7/8 MUD group than in the 8/8 MUD group (42.9% vs. 12.8%, P=0.001). The corresponding incidence in the 6-7/8 MRD group was comparable to that in the 8/8 MUD group (21.7% vs. 12.8%, P=0.332). There was no significant difference in the incidence of chronic GVHD (24.3%, 13.6%, and 17.9%, P=0.676), graft failure (2.4%, 8.0%, and 6.3%, P=0.551), overall survival (85.7%, 96.0%, and 87.5%, P=0.424), and failure-free survival (83.3%, 88.0%, and 83.3%, P=0.885) among the three groups (6-7/8 MUD, 6-7/8 MRD, and 8/8 MUD). In multivariate analysis, conditioning regimen without low-dose irradiation or busulfan was associated with an inferior failure-free survival (HR=2.973, P=0.042). In conclusion, after an intensified conditioning regimen with additional low-dose irradiation or busulfan, the outcome of HSCT from a 6-7/8 MRD or 6-7/8 MUD is comparable to that from an 8/8 MUD.

Indexed as

AdolescentAdultAnemia, AplasticBusulfanChildChild, PreschoolFemaleHistocompatibilityHLA AntigensHumansImmunosuppressive AgentsMaleProspective StudiesTransplantation ConditioningTreatment OutcomeUnrelated DonorsBusulfanHLA AntigensImmunosuppressive AgentsAllogeneic hematopoietic stem cell transplantationAlternative donorAplastic anemiaConditioning regimen

Identifiers

PMID33988738
OpenAlexW3161750533

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.